Ultimovacs has reported positive two-year data from the ongoing Phase I clinical trial, where its cancer vaccine, UV1, plus pembrolizumab to treat malignant melanoma showed robust overall survival.

A peptide-based vaccine, UV1 elicits a specific T cell response against the universal cancer antigen telomerase.

The company is developing UV1 as an off-the-shelf therapeutic cancer vaccine for usage along with other immunotherapies that need a continued T cell response for their mode of action.

In the trial, 30 patients were treated in two cohorts that only varied in the concentration of GM-CSF used as a vaccine adjuvant.

According to the latest overall survival data following treatment with UV1, the 24-month survival rate was reported to be 73% across all 30 subjects.

Trial subjects will be followed up for long-term survival.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

According to data reported in March from the trial, the complete response rate and the objective response rate were found to be 33% and 57%, respectively.

Prior trials with checkpoint inhibitors demonstrated that subjects with clinical responses have enhanced survival rates.

The company plans to report the three-year overall survival data from the first cohort of 20 patients in the fourth quarter of this year.

Ultimovacs CEO Carlos de Sousa said: “This result is the latest in a stream of highly encouraging data that indicate the effectiveness of UV1 in enhancing treatment of malignant melanoma.

“It underlines the potential of UV1 in promoting a concerted immune response in many solid tumour types including those in Ultimovacs’ broader phase II programmes.

“We have seen consistently more positive outcomes from UV1 in combination with pembrolizumab than with the checkpoint inhibitor alone – higher complete response rates, higher overall response rates, higher median progression-free survival and now better 24-month overall survival rates.”

In August last year, the company reported positive top-line data from the second cohort of its Phase I trial of UV1 plus pembrolizumab as a first-line therapy for metastatic malignant melanoma.